# The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

> **NCT00400231** · PHASE2 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 124 (estimated)

## Conditions studied

- Metabolic Syndrome x

## Interventions

- **DRUG:** Study drugs: Metformin and fenofibrate
- **DRUG:** Study Drug: Metformin
- **DRUG:** Study Drug: fenofibrate
- **DRUG:** Metformin and Fenofibrate placebo

## Key facts

- **NCT ID:** NCT00400231
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-12
- **Final completion:** 2008-03
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2017-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00400231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00400231, "The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00400231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*